AN OPEN-LABEL, PHASE 1/2 DOSE ESCALATION, DOSE EXPANSION AND COHORT EXPANSION STUDY EVALUATING THE SAFETY, PK AND CLINICAL ACTIVITY OF FMC-376 MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH KRAS G12C MUTATED ADVANCED SOLID TUMORS PROSPER

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT06244771

Study #:
STUDY00160949

Start Date:
Mar 28, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06244771

View Complete Trial Details & Eligibility at ClinicalTrials.gov